These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30170989)

  • 1. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With Prostate Cancer Phenotype and Clinical Outcome.
    Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of biochemical recurrence after Retzius-sparing robot-assisted radical prostatectomy: Analysis of 359 cases with a median follow-up period of 26 months.
    Abdel Raheem A; Chang KD; Alenzi MJ; Ham WS; Han WK; Choi YD; Rha KH
    Int J Urol; 2018 Dec; 25(12):1006-1014. PubMed ID: 30276864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
    Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
    Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of stromal and epithelial periostin expression in human prostate cancer: correlation with clinical pathological features and the risk of biochemical relapse or death.
    Nuzzo PV; Rubagotti A; Zinoli L; Ricci F; Salvi S; Boccardo S; Boccardo F
    BMC Cancer; 2012 Dec; 12():625. PubMed ID: 23273263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence.
    Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH
    PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
    Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
    Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
    Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
    BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
    Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
    Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Gleason score 3 + 4 = 7 prostate cancer with minimal amounts (<6%) vs ≥6% of Gleason pattern 4 tissue in needle biopsy specimens.
    Kır G; Seneldir H; Gumus E
    Ann Diagn Pathol; 2016 Feb; 20():48-51. PubMed ID: 26750655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.
    Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJ
    Eur J Cancer; 2016 Oct; 66():26-33. PubMed ID: 27522247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Significance for Long-Term Outcomes Following Radical Prostatectomy in Men with Prostate Cancer: Evaluation with Prostate Imaging Reporting and Data System Version 2.
    Kim R; Kim CK; Park JJ; Kim JH; Seo SI; Jeon SS; Lee HM
    Korean J Radiol; 2019 Feb; 20(2):256-264. PubMed ID: 30672165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibronectin and Periostin as Prognostic Markers in Ovarian Cancer.
    Kujawa KA; Zembala-Nożyńska E; Cortez AJ; Kujawa T; Kupryjańczyk J; Lisowska KM
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.